According to a recent announcement made by the drug-manufacturer from France, Sanofi-Aventis, it has stated that two patients, who were undergoing treatment for atrial fibrillation, had ended up with liver failure. Both the people involved in the case will require liver transplants.

It has also been reported that scientists have not been able to find out an exact cause behind the organ failures and its relationship with the disease and the medication.

Talking to Dow Jones Newswires, Spokesman for Sanofi Aventis, Jean-Marc Podvin said that the organization had already sent a communication to healthcare groups in the United States. Patient's safety was of the utmost importance to Sanofi and it was already coordinating with health authorities in Europe to check what could have been wrong with its drug known as Multaq.

Meanwhile, the US Food and Drug Administration has already issued a warning about the drug on its online portal. The regulator has already announced, what had happened to the two-people and how they had suffered the severe liver injury.

The chemical name for Multaq is dronedarone, and was first introduced to the market in 2009, and has since been prescribed to 200,000-people across the world. The total numbers of prescriptions issued in the US regarding Dronedarone have been stated to be around 492,000 alone for 147,000-patients.